Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
23 avr. 2020 09h00 HE
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, April 23, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
23 avr. 2020 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Norton Healthcare enrolls first patient in world for COVID-19 drug trial
21 avr. 2020 10h04 HE
|
Norton Healthcare
Louisville, KY, April 21, 2020 (GLOBE NEWSWIRE) -- A COVID-19 patient at Norton Healthcare is the first in the world to participate in a randomized Phase 2 clinical study using low-dose selinexor....
Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results
20 avr. 2020 16h06 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Notable Announces Leadership Team Expansion
09 avr. 2020 14h03 HE
|
Notable Labs
SAN FRANCISCO, April 09, 2020 (GLOBE NEWSWIRE) -- Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its...
BIOCARDIA REPORTS 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
09 avr. 2020 14h03 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
08 avr. 2020 07h30 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
06 avr. 2020 09h00 HE
|
American BriVision Holding Corporation
PDC-1421, the active ingredient of ABV-1505, is being expanded into Adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) A site monitoring visit for the...
首个抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动
06 avr. 2020 07h00 HE
|
Yiviva
—— 利用整合系统生物学方法，由耶鲁大学郑永齐教授和医起共同开发的首个抗肿瘤候选植物药 中国上海，美国纽约, April 06, 2020 (GLOBE NEWSWIRE) -- 生物制药创新企业医起医药科技有限公司（Yiviva Inc.），在2020年初正式启动了YIV-906联合索拉非尼治疗乙型肝炎相关性肝细胞癌（HCC）的一线疗法IIb期研究，并于今年三月迎来了第一位受试者。 ...
Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular Carcinoma
06 avr. 2020 07h00 HE
|
Yiviva
- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach -- Global study to evaluate efficacy, safety, and quality of life in patients with hepatitis...